1	Changes in vaginal Ureaplasma and Lactobacillus due to antibiotic regimen for
2	premature rupture of membranes
3	
4	Short title: Changes in vaginal Ureaplasma and Lactobacillus due to antibiotic regimen
5	
6	
7	Authors
8	Haruna Kawaguchi $^{1,2}$ $\P$ *, Yukiko Nakura $^{2\&}$ , Ryo Yamamoto $^{1},$ Shusaku Hayashi $^{1},$
9	Makoto Takeuchi <sup>3</sup> , Keisuke Ishii <sup>1</sup> , Itaru Yanagihara <sup>2</sup> ¶
10	1) Department of Maternal Fetal Medicine, Osaka Women's and Children's Hospital,
11	Osaka, Japan
12	2) Department of Developmental Medicine, Research Institute, Osaka Women's and
13	Children's Hospital, Osaka, Japan
14	3) Department of Pathology, Osaka Women's and Children's Hospital, Osaka, Japan
15	
16	*Correspondence author
17	E-mail: haruna@wch.opho.jp
18	<sup>¶</sup> These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 & These authors also contributed equally to this work.

20

#### 22 Abstract

23 Preterm premature rupture of membranes (PPROM) is associated with preterm delivery 24 and neonatal complications. PPROM is often complicated by intra-amniotic inflammation 25 and/or microbial invasion of the amniotic cavity with Ureaplasma or Mycoplasma. 26 Various prophylactic antibiotic therapies have been proposed to prolong latency between 27 PPROM and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal 28 complications. However, information on the potential of azithromycin administration to 29 reduce the microbial load of vaginal Ureaplasma and Mycoplasma remains lacking. This 30 prospective cohort study included singleton pregnancies managed with prophylactic 31 antibiotics for PPROM at less than 36 weeks of gestation. All patients received the 32 standard antibiotic regimen for PPROM, which consisted of a single oral azithromycin 33 and intravenous ampicillin every for 2 days followed by 5 days of oral amoxicillin. 34 Vaginal swabs samples were collected when PPROM was confirmed and after the 35 antibiotic regimen administration. The main outcome measures were to investigate the 36 changes in vaginal Ureaplasma, Mycoplasma, and Lactobacillus spp. due to the antibiotic 37 regimen. In addition, the association between the presence and changes in vaginal 38 Ureaplasma and Mycoplasma, pregnancy outcomes, and neonatal complications were 39 examined. Out of 82 eligible PPROM, 51 had positive vaginal Ureaplasma. Thirty-six

4

40	patients (52.2%) completed the antibiotic regimen. Among those with positive vaginal
41	Ureaplasma who completed the antibiotic regimen, 75% experienced an increase in
42	vaginal Ureaplasma levels. For those who delivered before completing all antibiotic
43	doses, 40% had increased vaginal Ureaplasma levels. Furthermore, the antibiotic regimen
44	resulted in decreased Lactobacillus spp. in almost all cases. However, vaginal
45	Ureaplasma changes were not found to be associated with neonatal sepsis or
46	bronchopulmonary dysplasia. This suggests that Ureaplasma became resistant to
47	azithromycin. Future studies are needed to revalidate current antibiotic therapy for
48	PPROM.
49	

50 Keywords: Azithromycin, bronchopulmonary dysplasia, funisitis, histological

- 51 chorioamnionitis, neonatal infection
- 52

# 53 Introduction

54	Preterm premature rupture of membranes (PPROM) occurs in 2%-3% of
55	pregnancies and is associated with preterm delivery, neonatal complications, and
56	maternal sepsis.(1-4) PPROM is often complicated by intra-amniotic inflammation
57	and/or microbial invasion of the amniotic cavity with Ureaplasma or Mycoplasma. (5)
58	Both are linked to neonatal infections and chronic lung disease. (6) Various
59	prophylactic antibiotic regimens were proposed to prolong the latency between PPROM
60	and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal
61	outcomes. (7-10) The American College of Obstetricians and Gynecologists
62	recommends using erythromycin and ampicillin, but a regimen with azithromycin has
63	been suggested as an alternative to erythromycin. (8, 11, 12)
64	At our institution, patients with PPROM receive a standard antibiotic regimen
65	consisting of a single oral dose of azithromycin and intravenous ampicillin for 2 days
66	followed by 5 days of oral amoxicillin. However, it is unclear whether administering
67	azithromycin can reduce the microbial load of vaginal Ureaplasma and Mycoplasma
68	DNA. Therefore, this study aimed to investigate the changes in vaginal Ureaplasma,
69	Mycoplasma, and Lactobacillus, as well as maternal blood Ureaplasma, resulting from
70	the antibiotic regimen used for PPROM cases. In addition, the association between the

- 71 presence and changes in vaginal *Ureaplasma* and *Mycoplasma*, pregnancy outcomes,
- 72 and neonatal complications were examined, and that aim was achieved.

#### 73 Materials and Methods

74	This single-center, prospective cohort study included singleton pregnancies
75	managed with prophylactic antibiotics for PPROM at less than 36 weeks of gestation
76	between October 2019 and December 2021. Patients under the age of 20, those who
77	received other antibiotics within 2 weeks of PPROM, and those allergic to ampicillin
78	and azithromycin were excluded. All relevant national regulations and institutional
79	policies were compiled, and the study was conducted under the tenets of the Helsinki
80	Declaration. It was approved by the ethical review board of Osaka Women's and
81	Children's Hospital (approval number, 1211; date of approval, June 3, 2019). Written
82	informed consent was obtained from all study subjects. Recruitment of subjects for this
83	study began on October 1, 2019 and ended on December 31, 2021. The standard
84	deviation of the amount of vaginal Ureaplasma colonization was 10 <sup>2.7</sup> . To have a 90%
85	power to detect changes above 10 <sup>2</sup> colony-forming units/mL, the study aimed to enroll
86	80 patients.
87	The perinatal management protocol for PPROM at our institution is as follows.
88	The diagnosis of PPROM is confirmed by observing amniotic fluid leakage from the
89	cervix or pooling in the vagina, along with positive diagnostic tests measuring vaginal
90	pH. In cases where the diagnosis is not clearly confirmed, an immunochromatographic

91	strip test with insulin-like growth factor-binding protein-1 (ActimProma <sup>®</sup> ) is used to
92	detect amniotic fluid in the vagina or ultrasound evaluation is used to confirm the
93	presence of oligohydramnios. All patients were admitted to the hospital and received the
94	standard antibiotic regimen for PPROM before 36 weeks of gestation with intravenous
95	ampicillin (2 g dose every 6 hours) for 48 hours and single oral azithromycin (1 g dose)
96	followed by oral amoxicillin (500 mg dose every 8 hours) for 5 days. Betamethasone
97	was administrated for patients with gestational age less than 34 weeks and imminent
98	delivery. Intravenous magnesium sulfate and/or ritodrine hydrochloride and/or oral
99	nifedipine as tocolytic agents were administered when patients have short cervical
100	length and frequent uterine contraction. Indications for delivery included clinical
101	chorioamnionitis, onset of labor, nonreassuring fetal status, or gestational age beyond
102	36 weeks. Clinical chorioamnionitis was diagnosed based on the presence of maternal
103	fever (≥38.0°C) and two or more clinical signs: maternal leukocytosis (white blood cell
104	count >15,000/mm <sup>3</sup> ), maternal tachycardia (heart rate > 100 beats/min), fetal
105	tachycardia (heart rate > 160 beats/min), uterine tenderness, and purulent or foul-
106	smelling amniotic fluid or vaginal discharge. (13)
107	Vaginal swabs and maternal blood samples were collected from women when
108	the diagnosis of PPROM was confirmed. The quantity of vaginal secretions was

109	measured by weighing the swab tube before and after the collection. Vaginal swabs
110	were taken from the lateral vaginal walls and the anterior and posterior fornix, and they
111	were transferred to a cobas® polymerase chain reaction (PCR) Media Dual Swab
112	Sample Kit from Roche Diagnostics GmbH, Germany. Vaginal swabs and maternal
113	blood samples were retaken after the completion of the antibiotic regimen. Scrapings of
114	the placental surface were also performed. If delivery occurred before the completion of
115	the regimen, vaginal swabs and maternal blood samples were collected before the
116	delivery. These results were not available to managing clinicians. The amount and
117	species of Ureaplasma collected from the vaginal secretions, along with the amount of
118	Lactobacillus spp. and Mycoplasma (M.) hominis and the presence of inerolysin (pore-
119	forming toxin produced by Lactobacillus (L.) iners that can cause preterm labor) were
120	determined using real-time PCR. The amount of Ureaplasma was also measured from
121	maternal blood and placental surface. An increase or decrease of 10 <sup>2</sup> or more in DNA
122	copy numbers was considered significant.
123	This study investigated neonatal and infant mortality and any of the following
124	adverse perinatal outcomes for up to 6 months of age: neonatal intensive care unit
125	admission, mechanical ventilation, respiratory distress syndrome, retinopathy of
126	prematurity, intraventricular hemorrhage 3 or 4 grade, periventricular leukomalacia,

10
----

127	necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia (BPD), and
128	congenital anomaly. BPD is a chronic lung disease, which is most commonly seen in
129	premature infants requiring respiratory support, including oxygen supplementation at 36
130	weeks corrected gestational age. (14) Neonatal sepsis is defined as the presence of a
131	positive blood culture. (15)
132	In this study, changes in vaginal Ureaplasma, Mycoplasma, and Lactobacillus
133	are divided into two groups: complete and incomplete antibiotic protocols. Cases of
134	complete protocol are defined as cases in which all antibiotic regimens had been
135	completed. Cases of incomplete protocol are those who delivered in the middle of their
136	antibiotic regimen, but all of them had received at least one intravenous ampicillin and
137	oral azithromycin administration.
138	
139	DNA extraction and quantitative real-time PCR of Ureaplasma
140	DNA was extracted from vaginal swab and maternal blood samples using a Maxwell®
141	RSC Blood DNA Kit (AS1400, Promega, Japan). The DNA copy number of
142	Ureaplasma was measured using QuantStudio 5Real-Time PCR System (Thermo Fisher
143	Scientific) targeted for the 16S ribosomal RNA gene. The amplification reaction
144	mixtures comprised 5 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher

145	Scientific), primers	(0.9 µM	each), probe	(Thermo Fisher	Scientific, 0.25	μM), and 1	μL
-----	----------------------	---------	--------------	----------------	------------------	------------	----

- 146 of DNA sample; this was adjusted to 10  $\mu$ L with DDW. The primers and probe used
- 147 were as follows: 16S-Urea F1(AGGCATGCGTCTAGGGTAGGA), 16S-Urea
- 148 R1(ACGTTCTCGTAGGGATACCTTGTTA), and 16S-Urea-FAM-MGB
- 149 probe (FAM-CGGTGACTGGAGTTAA-MGB).
- 150 The PCR conditions were as follows: predenaturation at 95°C for 20 s, 40 cycles of
- 151 denaturation at 95°C for 1 s, and annealing at 58 C for 20 s.
- 152 The standard curve of *Ureaplasma* was determined using serial dilutions with copy
- numbers of  $1.0 \times 10^1$  to  $1.0 \times 10^6$  copies per reaction mixture by real-time PCR. In each
- 154 run with clinical specimens, negative control and standards were included. To
- 155 differentiate Ureaplasma (U.) parvum from U. urealyticum, the following primers and
- 156 probes were used: ureG F2(CAACATTTAGTCCAGATTTAG), ureG
- 157 R2(TAGCACCAACATAAGGAG), Up-FAM-MGB probe (FAM-
- 158 TTGACCACCCTTACGAG-MGB), and Uu-VIC-MGB probe (VIC-
- 159 TTGTCCGCCTTTACGAG-MGB). The amplification reaction mixtures comprised 5
- 160 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), primers (0.9 µM
- 161 each), probes (Thermo Fisher Scientific, 0.2 µM each), and 1 µL of sample DNA; this
- 162 was adjusted to 10  $\mu$ L with DDW.

- 164 Quantitative real-time PCR analysis of *M. hominis*
- 165 The primers and probe used were as follows:
- 166 Mh-yidC-F(ACCCGGTTTAGTGAGTTTGCT), Mh-yidC-R
- 167 (CCTCAGTTTATTGCATTGCCA), and Mh-yidC-VIC probe (VIC-
- 168 AACAAGCAACCTGATATT-MGB). The PCR conditions were as follows:
- 169 predenaturation at 95°C for 20 s, 35 cycles of denaturation at 95°C for 1 s, and
- 170 annealing at 60°C for 20 s.
- 171
- 172 Quantitative real-time PCR of *Lactobacillus* species and inerolysin detection
- 173 The primers for *Lactobacillus* spp. used were Lacto-F
- 174 (TGGAAACAGRTGCTAATACCG) and Lacto-R
- 175 (GTCCATTGTGGAAGATTCCC).(16) The primers for inerolysin were; inerolysin-
- 176 F(CGTGGTCGTACATCAGGCTT) and inerolysin-
- 177 R(TTCTCCACCATTCCCATGCC).
- 178 PCRs were performed in a reaction volume of 10  $\mu$ L, each containing 0.5  $\mu$ M of
- 179 inerolysin-F and inerolysin-R primers, 5 µL of PowerUP<sup>TM</sup> SYBR<sup>TM</sup> Green Master Mix
- 180 (Thermo Fisher Scientific), and 1.0 µL of genomic DNA. PCR amplification was

#### 181 performed under the following conditions: initial cycle of 95°C for 2 min, 35 cycles of

- 182 95°C for 1 s, 58°C for 15 s, and 72°C for 60 s.
- 183

184 2.4 Statistical analysis

- 185 Categorical and continuous variables were analyzed using chi-square or Fisher's exact
- 186 tests and compared using Kruskal–Wallis test. Multivariate logistic regression analyses
- 187 were performed to examine the adjusted odds ratios (aOR) and 95% confidence
- 188 intervals (CI) for changes in Ureaplasma and perinatal outcomes. Statistical
- 189 significance was set at P <0.05. Two-sided P-values were reported, and analyses were
- 190 conducted using a JMP software (version 14; SAS Institute, Cary, NC, USA).

#### 192 Results

193	In total, 82 patients with PPROM were included, and 51 were positive for
194	vaginal Ureaplasma. Thirty-six patients (52.2%) completed the standard antibiotic
195	regimen. (Figure 1) Of those who had positive vaginal Ureaplasma and completed the
196	standard antibiotic regimen, vaginal Ureaplasma increased in 18 patients (75%).
197	Among patients with positive vaginal Ureaplasma who delivered before the completion
198	of all antibiotic doses, vaginal Ureaplasma increased in eight patients (40%).
199	
200	Fig 1. Flowchart of the study population.
201	A total of 82 patients with PPROM were eligible for this study. Vaginal Ureaplasma
202	was positive in 51 patients and negative in 31 patients. Of the patients who had positive
203	vaginal Ureaplasma and completed the standard antibiotic regimen, 18 (75%) had
204	increased vaginal Ureaplasma after treatment. Among patients with a positive vaginal
205	Ureaplasma delivered before completion of all antibiotic doses, vaginal Ureaplasma
206	increased in eight patients (40%).
207	PPROM, preterm premature rupture of membranes; NEG, negative
208	* intravenous 2 g ampicillin every 6 hours for 2 days, a single oral dose of 1 g
209	azithromycin, and 5 days of oral 500 mg amoxicillin every 8 hours.

210	Fig 2.	The change of micro	bial load of vagina	l Ureaplasma DNA	before and after
-----	--------	---------------------	---------------------	------------------	------------------

- antibiotic regimen.
- 212 There were many cases of increased vaginal Ureaplasma, especially in patients who had
- 213 completed the antibiotic regimen.
- \* intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of
- azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours.
- 216 Fig 3. The change of microbial load of vaginal Lactobacillus spp. DNA before and
- after antibiotic regimen.
- 218 Almost all Lactobacillus spp. were decreased or disappeared after the antibiotic
- 219 regimen, especially in the cases that completed the antibiotic regimen.
- \* intravenous 2 g ampicillin every 6 hours for 2 days, a single oral dose of 1 g
- azithromycin, and 5 days of oral 500 mg amoxicillin every 8 hours.
- Table 1 shows the maternal characteristics and perinatal findings classified into
- 223 three groups based on vaginal Ureaplasma changes: Ureaplasma-negative before and
- 224 after the antibiotic regimen, Ureaplasma-positive that decreased after the antibiotic
- regimen, and *Ureaplasma*-positive that increased after the antibiotic regimen.

# 227 Table 1. Maternal characteristics and perinatal findings, classified into three groups

228	based on v	vaginal	Ureaplasma	changes	by	antibiotic	treatment
-----	------------	---------	------------	---------	----	------------	-----------

		Ureaplasma	Ureaplasma (+	-) at the time	
		(-) at the time	of PPROM		
	Total	of PPROM	Decreased	Increased	p
			after	after	
			treatment	treatment	
	N = 69	N = 24	N = 18	N = 27	
maternal age at	33(23-46)	35 (26–46)	31.5 (22–41)	33 (23–42)	0.21
delivery					
nulliparous	40	10 (41.7)	14 (77.8)	16 (59.3)	0.06
history of	4	1 (4.2)	0	3 (11.1)	0.27
preterm birth					
Obesity (BMI	11	4 (16.7)	4 (22.2)	3 (11.1)	0.6
≧25)					
ART	10	3 (12.5)	2 (11.1)	5 (18.5)	0.74
tobacco use	4	1 (4.2)	1 (5.6)	2 (7.4)	0.88
during					
pregnancy					
СНТ	1	1 (4.2)	0	0	-
DM	0	0	0	0	-

history of	7	1 (4.2)	0	6 (22.2)	0.02
cervical					6
conization					
cerclage	6	2 (8.3)	2 (11.1)	2 (7.4)	0.91
antenatal	38	14 (58.3)	10 (55.6)	14 (51.9)	0.9
corticosteroid					
tocolysis <sup>a</sup>	39	13 (54.2)	10 (55.6)	16 (59.3)	0.93
HDP	4	2 (8.3)	0	2 (7.4)	0.47
GDM	7	1 (4.6)	3 (17.6)	3 (11.5)	0.42
antibiotics	69	24 (100)	18 (100)	27 (100)	-
complete	36	11 (45.8)	6 (33.3)	19 (70.4)	0.03
protocol <sup>b</sup>					8
azithromycin	69	24 (100)	18 (100)	27 (100)	-
GA at PPROM	31 + 6 (12 +	32 + 3 (20 + 0	32 + 2 (17 +	31 + 3 (12	0.43
	5~35+6)	$\sim$ 35 + 6)	6~35+3)	$+5\sim35+$	
				2)	
GA at delivery	33 + 1 (17 +	33 + 2 (23 + 0	33 + 3 (18 +	32+4 (17	0.83
	5~36 + 4)	$\sim$ 36 + 4)	$1 \sim 36 + 1)$	$+5\sim 36+$	
				3)	
Latency <sup>c</sup>	7 (0-86)	5 (0-86)	3.5 (0-21)	10 (2–52)	0.01
					2

18

Latency <	33	13 (54.2)	12 (66.7)	8 (29.6)	0.03
7days					8
CS	25	10 (41.7)	3 (16.7)	12 (44.4)	0.13
hCAM	39	12 (54.6)	8 (50)	19 (76)	0.17
Funisitis	30	9 (40.9)	4 (25)	17 (68)	0.02

229 Data are expressed as the median (range) or n (%)

<sup>230</sup> <sup>a</sup> Tocolysis agents are intravenous magnesium sulfate and/or ritodrine hydrochloride

- and/or oral nifedipine.
- <sup>b</sup> Complete protocol is defined as the cases in which all standard antibiotic regimens
- 233 (intravenous 2 g ampicillin every 6 hours for 2 days, one oral dose of 1 g azithromycin,
- and 5 days of oral 500 mg amoxicillin every 8 hours) had been completed.
- <sup>c</sup> The latency is defined as the period between PPROM and delivery.
- 236 BMI, body mass index; ART, assisted reproductive technology; CHT, chronic
- 237 hypertension; DM, diabetes mellitus; HDP, hypertensive disorders of pregnancy; GDM,
- 238 gestational diabetes mellitus; GA, gestational age; PPROM, preterm premature rupture
- 239 of membranes; CS, cesarean section; hCAM, histological chorioamnionitis

- 241 The median gestational week at PPROM and delivery did not differ among the
- 242 three groups. However, latency from PPROM to delivery was significantly prolonged in

243	the group with increased Ureaplasma after the antibiotic regimen. There was no
244	difference in the incidence of histological chorioamnionitis (hCAM), but funisitis was
245	significantly more common in the group with increased Ureaplasma after the antibiotic
246	regimen ( $p = 0.02$ ).
247	Figure 2 shows the changes in vaginal Ureaplasma spp. before and after the
248	antibiotic regimen. The median microbial load of vaginal Ureaplasma DNA at the time
249	of PPROM was $1.9 \times 10^7 (1.8 \times 10^2 - 4.6 \times 10^9)$ . Many cases had increased vaginal
250	Ureaplasma, especially in patients who completed the antibiotic regimen. As shown in
251	Figure 3, Lactobacillus spp. decreased after the antibiotic regimen in almost all cases.
252	Table 2 shows the vaginal and maternal blood Ureaplasma, vaginal M. hominis,
253	Lactobacillus spp., and inerolysin classified by vaginal Ureaplasma changes. All M.
254	hominis-positive cases were positive for vaginal Ureaplasma. Three patients had a
255	positive vaginal <i>M. hominis</i> result at the time of PPROM and did not decrease in all
256	cases after antibiotic regimen, but rather turned positive in three new cases. The loss of
257	Lactobacillus spp. was more common in patients who completed the antibiotic regimen,
258	especially in the group with increased Ureaplasma. hCAM and funisitis were more
259	common in those with completed antibiotic regimen, regardless of vaginal Ureaplasma
260	changes due to the antibiotic regimen and presence of Ureaplasma at the time of

261	PPROM (aOR,7.5; 95%	CI; 2.1–26.6; $P =$	0.002, aOR4.5; 95%CI	1.4-11.4; P = 0.01,
-----	---------------------	---------------------	----------------------	---------------------

- 262 respectively). Among incomplete the antibiotic regimen, there were less funisitis in the
- 263 group with decreased *Ureaplasma* due to antibiotic therapy than in the group with
- 264 increased or negative *Ureaplasma* at the time of PPROM.
- 265
- 266 Table 2. Ureaplasma in vagina and maternal blood, vaginal Mycoplasma hominis,
- 267 vaginal Lactobacillus spp, and inerolysin classified by whether the antibiotic regimen

268 was completed or not and how vaginal *Ureaplasma* was changed

			complete protocol			uncomplete protocol			
			Ureaplasm	a(+) at the	Ureapl	Ureaplasma (+) at the		Urea	
			time of PPF	ROM	asma	time of PPROM		plasm	
			increased	decreased	(-) at	increase	decreased	a (-)	
			Ureaplas	Ureaplas	the	d	Ureaplasm	at the	
			ma after	ma after	time of	Ureapla	<i>a</i> after	time	
			antibiotic	antibiotic	PPRO	sma	antibiotic	of	
			regimen	regimen	М	after	regimen	PPRO	
						antibioti		М	
						c			
						regimen			
		N	18	6	12	8	12	13	
befor	vaginal	Up	15	3	-	5	10	-	

e	Ureaplasm	Uu	3	2	-	3	3	-
antib	a						(duplicatio	
iotic							n1)	
regi		unkno	0	1	-	0	0	_
men		wn						
	vaginal Urea	plasma	1.8 × 10 <sup>7</sup>	$6.8 \times 10^{8}$	_	1.1 × 10 <sup>7</sup>	$1.2 \times 10^{8}$	_
	DNA (cp/mL	.)	(1.7 ×	(1.8 ×		(3.7 ×	$(6.8 \times 10^{2} -$	
			104–2.3 ×	10 <sup>2</sup> -4.6 ×		105-2.2	1.4 × 10 <sup>9</sup> )	
			108)	109)		× 10 <sup>8</sup> )		
	maternal bloc	od	0	1	0	0	0	0
	Ureaplasma	(+)						
	vaginal M. he	ominis	2 (11.1)	0	0	0	1 (8.3)	0
	(+)							
	vaginal		15 (83.3)	6 (100)	11	8 (100)	12 (100)	13
	Lactobacillus	s (+)			(91.7)			(100)
	Inerolysin (+	)	9/15 (60)	3/6 (50)	6/11	4/8 (50)	10/12	3/13
	among Lactb	acillus			(54.5)		(83.3)	(23.1)
after	vaginal Urea	plasma	$4.8 \times 10^{7}$	8.0 × 10 <sup>6</sup>	1.7 ×	4.1 × 10 <sup>8</sup>	$4.2 \times 10^{6}$	_
antib			(2.8 ×	(0–7.9 ×	106	(8.7 ×	(0–7.3 ×	
iotic			10 <sup>7</sup> -6.9 ×	107)	(positi	106-3.4	108)	
regi			109)		ve	× 10 <sup>10</sup> )		
men					conver			
					sion1)			
	maternal bloc	od	0	1 (16.7)	0	1 (12.5)	0	0
	Ureaplasma	(+)						
	vaginal M. he	ominis	4 (22.2)	1 (16.7)	0	0	1 (8.3)	0
	(+)							

22

	vaginal	decrea	15 (100)	6 (100)	10	8 (100)	12 (100)	11
	Lactobacill	se			(90.9)			(84.6)
	us	loss	12 (80)	4 (66.7)	5	4 (50)	4 (33.3)	2
					(45.4)			(15.4)
	Inerolysin (+)	)	1/6 (16.7)	0	4/6	0	1/8 (12.5)	0
	among Lactb	acillus			(66.7)			
Ureapi	lasma in the pl	acenta	14 (87.5)	3 (75)	0	8 (100)	8 (72.7)	1
(unexa	mined)		(n = 2)	(n = 2)	(n = 1)		(n = 1)	(n =
								1)
hCAM	[		14 (82.3)	4 (100)	9	4 (57.1)	4 (33.3)	4
(unexa	mined)		(n = 1)	(n = 2)	(81.8)	(n = 1)		(33.3)
					(n = 1)			(n =
								1)
Funisit	is		12 (70.6)	3 (60)	7	4 (57.1)	1 (8.3)	2
					(63.6)			(16.7)

#### 269

270 Data are expressed as the median (range) or n (%).

271 PPROM, preterm premature rupture of membranes; Up, Ureaplasma parvum; Uu,

272 Ureaplasma urealyticum; M. hominis, Mycoplasma hominis; hCAM, histological

273 chorioamnionitis

274

Table 3 shows the neonatal complications according to vaginal *Ureaplasma* 

changes. Vaginal *Ureaplasma* changes were not associated with neonatal intensive care

277	unit admission.	neonatal	sepsis.	mechanical	ventilation.	or BPD.	However,	BPD v	was
					,				

- 278 more frequent in those who completed protocol than in those who did not complete the
- 279 protocol, regardless of vaginal *Ureaplasma* changes due to the antibiotic regimen,
- 280 presence of *Ureaplasma* at the time of PPROM, and gestational age at delivery. (aOR,
- 281 7.2; 95%CI 1.3–40.1; *P* = 0.02)
- Table 3. The neonatal complications according to vaginal *Ureaplasma* changes
- 283 due to the antibiotic regimen

	Total	Ureaplasma	Ureaplasma	-positive	
		- negative	decreased	increased	
			after	after	
			treatment	treatment	
	N = 69	N = 24	N = 18	N = 27	
Stillbirth	4	1 (4.2)	1 (5.6)	2 (7.4)	
neonatal death	1	0	0	1 (3.7)	
infant death	2	1	0	1 (3.7)	
delivery at other	4	1	2	1	
hospital					
infant outcome <sup>a</sup>	N = 60	N = 22	N = 15	N = 23	p
birth weight(g)	2018 (520-	1957 (692–	2172 (864–	2016 (520-	0.97
	3010)	2918)	2958)	3010)	
NICU admission	54 (90)	21 (95.5)	14 (93.3)	19 (82.6)	0.32
male infant	37 (61.7)	15 (68.2)	10 (66.7)	12 (52.3)	0.49
Apgar score $(5) < 7$	7 (11.7)	3 (13.6)	2 (13.3)	2 (8.7)	0.85
pH < 7.1	0	0	0	0	-
mechanical	27 (45)	9 (40.9)	5 (33.3)	13 (56.5)	0.33
ventilation					
RDS	18 (30)	6 (27.3)	4 (26.7)	8 (34.8)	0.82
ROP	13 (21.7)	5 (22.7)	3 (20)	5 (21.7)	0.98

25

IVH 3,4	0	0	0	0	-
PVL	0	0	0	0	-
NEC	1 (1.7)	1 (4.5)	0	0	0.42
neonatal sepsis	5 (8.3)	2 (9.1)	1 (6.7)	2 (8.7)	0.96
BPD	15 (25)	5 (22.7)	4 (26.7)	6 (26.1)	0.95
congenital anomaly	11 (18.3)	5 (22.7)	3 (20)	3 (13.0)	0.69

284

285 Data are expressed as the median (range) or n (%).

<sup>a</sup>After excluding four cases delivered at other hospitals, four stillbirths, and one early

287 neonatal death, 60 cases were included in the study of infant complications.

288 NICU, neonatal intensive care unit; RDS, respiratory distress syndrome; ROP,

289 retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular

290 leukomalacia; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia

291

# 293 Discussion

294	Almost all Lactobacillus spp. decreased or disappeared, while most vaginal
295	Ureaplasma and M. hominis increased after the antibiotic regimen, particularly in
296	patients who completed the regimen. Patients with increased vaginal Ureaplasma had
297	longer latency. This result did not indicate that cases of increased Ureaplasma would
298	have a longer latency period. Rather, the longer period reflected Ureaplasma that was
299	not reduced by antibiotic therapy grew intravaginally. The longer latency from PPROM
300	may increase the likelihood of ascending infection of Ureaplasma to the amnion despite
301	the antibiotic therapy. The possibility of avoiding invasive amniocentesis was
302	considered if Ureaplasma could be detected in maternal blood in the presence of
303	intrauterine Ureaplasma infection. However, it was impractical because Ureaplasma in
304	maternal blood was undetectable in most cases.
305	Antibiotics were recommended for women with PPROM to prolong the
306	delivery latency interval and reduce chorioamnionitis and neonatal sepsis.(8, 9, 17, 18)
307	A regimen of intravenous ampicillin and erythromycin followed by oral amoxicillin and
308	erythromycin has been commonly used. (8) Recently, azithromycin has been used
309	instead of erythromycin because of its low cost, better side effect profile, ease of
310	administration, and antibiotic resistance. The resistance of Ureaplasma and

311	Mycoplasma to erythromycin was reported to be over 80%. (19) Azithromycin was
312	associated with a similar latency interval and lower rate of clinical chorioamnionitis for
313	women with PPROM.(12, 20) Tanaka reported the eradication of Ureaplasma in the
314	amniotic fluid of patients with PPROM treated with intravenous ampicillin-sulbactam
315	and oral azithromycin.(21) Kacerovsky showed that intravenous clarithromycin was
316	related to the reduced Ureaplasma DNA load in the amniotic fluid of patients with
317	PPROM.(10) Conversely, Gomez reported that antibiotic administration (ceftriaxone,
318	clindamycin, and erythromycin for 10-14 days) rarely eradicates intra-amniotic
319	infection in patients with preterm PROM.(22) A report showed that azithromycin
320	effectively eradicated respiratory tract Ureaplasma colonization in preterm infants. (23)
321	In this study, most vaginal Ureaplasma was increased after the antibiotic regimen,
322	suggesting an increasing resistance of Ureaplasma to azithromycin. In previous reports,
323	the resistance rates of U. urealyticum and M. hominis to azithromycin also increased by
324	about 14%–19.5%. (24, 25)
325	In this study, there was an increased frequency of hCAM, funisitis, and BPD in
326	cases that completed the antibiotic regimen. An increased vaginal Ureaplasma
327	increased the frequency of funisitis but not the incidence of neonatal infection and BPD.
328	These suggest that even if the antibiotic regimen contributes to a prolonged gestational

329	age, it may increase the frequency of intrauterine infection or neonatal infection from
330	proliferated Ureaplasma and decreased Lactobacillus spp. Many studies presented that
331	Ureaplasma was associated with adverse pregnancy outcomes and neonatal morbidities,
332	such as preterm delivery, PPROM, chorioamnionitis, BPD,(6, 26) intraventricular
333	hemorrhage,(27) and necrotizing enterocolitis.(28) Macrolides have anti-inflammatory
334	properties that might reduce lung damage in preterm infants and treat bacterial
335	infections(29); they reduce BPD in preterm infants. (30, 31) In this study, respiratory
336	samples from infants were not obtained for Ureaplasma culture, so it was unknown
337	whether the infants had Ureaplasma infection. The sample size was insufficient to
338	validate the neonatal morbidity, so further research is needed.
339	Lactobacillus, the most frequently isolated microorganism from a healthy
340	human vagina, is touted to prevent the invasion of pathogens and ensure vaginal
341	epithelial homeostasis. (32) The loss of <i>Lactobacillus</i> and increase in Gram-negative
342	rods, such as Gardnerella vaginalis, lead to bacterial vaginosis. (33) In a recent study,
343	L. crispatus, L. gasseri, L. jensenii, and L. iners, were the most frequently isolated in the
344	vaginas of healthy childbearing age or pregnant women. (34) A vaginal microbiota that
345	is rich in L. crispatus, L. gasseri, and L. jensenii is often associated with a lower risk of
346	bacterial vaginosis and preterm birth. Conversely, L. iners may play a role in the

347	pathogenesis of bacterial vaginosis associated with preterm birth.(35, 36) L. iners alone
348	detected in vaginal smears of healthy women in early pregnancy might be related to
349	preterm delivery.(35) L. iners secretes the cholesterol-dependent cytolysins (CDC),
350	inerolysin, as well as one of the CDC family, vaginolysin, produced by G. vaginalis.
351	(37) In this study, about half of the cases had inerolysin, which may be related to the
352	fact that the subjects in this study were cases of PPROM. There was no difference in the
353	increase in vaginal Ureaplasma with or without inerolysin. Lactobacillus spp. was
354	decreased after the antibiotics therapy regardless of the presence or absence of
355	inerolysin. It is unclear whether Lactobacillus spp., reduced by antibiotic therapy, will
356	recover spontaneously. It may be challenging to reduce Ureaplasma with this antibiotic
357	therapy; we may rather focus on Lactobacillus formulations.
358	The strength of this study is that it is the first to investigate both vaginal
359	Ureaplasma and Lactobacillus changes caused by ampicillin and azithromycin
360	regimens. This was also an examination at a single institution with a uniform
361	management policy. However, it has several limitations. In this study, vaginal cultures
362	were collected rather than from amniotic fluid through transabdominal amniocentesis,
363	which does not directly indicate amniotic fluid infection. There were three reasons why
364	the specimens were vaginal secretions. First, the purpose of this study was to observe

365	changes in both Ureaplasma and Lactobacillus due to antibiotic administration. Second,
366	in PPROM cases, amniotic fluid testing after antibiotic administration might not be
367	available due to the almost complete loss of amniotic fluid in the uterine cavity or the
368	rapid onset of labor. Third, amniocentesis was invasive. In almost all vaginal
369	Ureaplasma-positive cases, Ureaplasma was found on the surface of the placenta,
370	regardless of the delivery mode and vaginal Ureaplasma changes due to the antibiotic
371	regimen. Although there may be contaminations during delivery in PPROM cases, most
372	vaginal Ureaplasma may be ascending into amniotic fluid or placenta. Another
373	limitation is that the sample size was insufficient to validate the neonatal morbidity.
374	

# 375 Conclusions

- 376 Almost all *Lactobacillus* spp. decreased while most vaginal *Ureaplasma and M*.
- 377 *hominis* increased after the antibiotic regimen. This suggests that *Ureaplasma* and *M*.
- 378 *hominis* became resistant to azithromycin. Future studies are needed to revalidate
- 379 current antibiotic therapy for PPROM because azithromycin-resistant Ureaplasma and
- 380 *M. hominis* are widespread in the vaginal tract.
- 381
- 382
- 383

# 384 Acknowledgements

- 385 We gratefully acknowledge the work of the medical staff of our center for their
- 386 assistance in specimen collection.

### 388 References

Mercer BM. Preterm premature rupture of the membranes. Obstetrics and
 gynecology. 2003;101(1):178-93.

Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
 preterm birth. Lancet (London, England). 2008;371(9606):75-84.

393 3. Lorthe E, Torchin H, Delorme P, Ancel PY, Marchand-Martin L, Foix-L'Hélias
394 L, et al. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and
395 2-year outcomes within a national population-based study (EPIPAGE-2). American
396 journal of obstetrics and gynecology. 2018;219(3):298.e1-.e14.

Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al.
Immediate delivery compared with expectant management after preterm pre-labour
rupture of the membranes close to term (PPROMT trial): a randomised controlled trial.
Lancet (London, England). 2016;387(10017):444-52.

401 5. Paramel Jayaprakash T, Wagner EC, van Schalkwyk J, Albert AY, Hill JE,
402 Money DM. High Diversity and Variability in the Vaginal Microbiome in Women
403 following Preterm Premature Rupture of Membranes (PPROM): A Prospective Cohort
404 Study. PloS one. 2016;11(11):e0166794.

405 6. Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et
406 al. Association between pulmonary ureaplasma colonization and bronchopulmonary
407 dysplasia in preterm infants: updated systematic review and meta-analysis. The Pediatric
408 infectious disease journal. 2014;33(7):697-702.

Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic
regimen treats and prevents intra-amniotic inflammation/infection in patients with
preterm PROM. The journal of maternal-fetal & neonatal medicine : the official journal
of the European Association of Perinatal Medicine, the Federation of Asia and Oceania
Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(17):2727-37.

8. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD,
et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture
of the membranes. A randomized controlled trial. National Institute of Child Health and
Human Development Maternal-Fetal Medicine Units Network. Jama. 1997;278(12):98995.

419 9. Mercer BM, Arheart KL. Antimicrobial therapy in expectant management of
420 preterm premature rupture of the membranes. Lancet (London, England).
421 1995;346(8985):1271-9.

422 10. Kacerovsky M, Romero R, Stepan M, Stranik J, Maly J, Pliskova L, et al.
423 Antibiotic administration reduces the rate of intraamniotic inflammation in preterm

424 prelabor rupture of the membranes. American journal of obstetrics and gynecology.
425 2020;223(1):114.e1-.e20.

426 11. Siegler Y, Weiner Z, Solt I. ACOG Practice Bulletin No. 217: Prelabor Rupture
427 of Membranes. Obstetrics and gynecology. 2020;136(5):1061.

428 12. Seaman RD, Kopkin RH, Turrentine MA. Erythromycin vs azithromycin for
429 treatment of preterm prelabor rupture of membranes: a systematic review and meta430 analysis. American journal of obstetrics and gynecology. 2022;226(6):794-801.e1.

431 13. Hollander D. Diagnosis of chorioamnionitis. Clinical obstetrics and gynecology.
432 1986;29(4):816-25.

433 14. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American journal of
434 respiratory and critical care medicine. 2001;163(7):1723-9.

435 15. Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for
436 a neonatal-specific consensus definition for sepsis. Pediatric critical care medicine : a
437 journal of the Society of Critical Care Medicine and the World Federation of Pediatric
438 Intensive and Critical Care Societies. 2014;15(6):523-8.

439 16. Byun R, Nadkarni MA, Chhour KL, Martin FE, Jacques NA, Hunter N.
440 Quantitative analysis of diverse Lactobacillus species present in advanced dental caries.
441 Journal of clinical microbiology. 2004;42(7):3128-36.

Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for
preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.
ORACLE Collaborative Group. Lancet (London, England). 2001;357(9261):979-88.

445 18. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217.
446 Obstetrics and gynecology. 2020;135(3):e80-e97.

447 19. Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM.
448 Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in
449 pregnant women. BMC infectious diseases. 2014;14:171.

Azithromycin vs erythromycin for the management of preterm premature rupture of
membranes. American journal of obstetrics and gynecology. 2019;221(2):144.e1-.e8.

Tanaka S, Tsumura K, Nakura Y, Tokuda T, Nakahashi H, Yamamoto T, et al.
New antibiotic regimen for preterm premature rupture of membrane reduces the incidence
of bronchopulmonary dysplasia. The journal of obstetrics and gynaecology research.
2019;45(5):967-73.

Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, et al. Antibiotic
administration to patients with preterm premature rupture of membranes does not
eradicate intra-amniotic infection. The journal of maternal-fetal & neonatal medicine :

the official journal of the European Association of Perinatal Medicine, the Federation of
Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.
2007;20(2):167-73.

463 23. Viscardi RM, Terrin ML, Magder LS, Davis NL, Dulkerian SJ, Waites KB, et
464 al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. Archives
465 of disease in childhood Fetal and neonatal edition. 2020;105(6):615-22.

Zhang W, Li L, Zhang X, Fang H, Chen H, Rong C. Infection Prevalence and
Antibiotic Resistance Levels in Ureaplasma urealyticum and Mycoplasma hominis in
Gynecological Outpatients of a Tertiary Hospital in China from 2015 to 2018. The
Canadian journal of infectious diseases & medical microbiology = Journal canadien des
maladies infectieuses et de la microbiologie medicale. 2021;2021:8842267.

Zhang S, Xu K, Liu SX, Ye XL, Huang P, Jiang HJ. Retrospective Analysis of
Azithromycin-Resistant Ureaplasma urealyticum and Mycoplasma hominis Cervical
Infection Among Pregnant Women. Infection and drug resistance. 2023;16:3541-9.

474 26. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD.
475 Pulmonary Ureaplasma urealyticum is associated with the development of acute lung
476 inflammation and chronic lung disease in preterm infants. Pediatric research.
477 2004;55(1):61-8.

478 27. Kasper DC, Mechtler TP, Böhm J, Petricevic L, Gleiss A, Spergser J, et al. In
479 utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary
480 dysplasia and intraventricular hemorrhage in preterm infants. Journal of perinatal
481 medicine. 2011;39(3):331-6.

482 28. Okogbule-Wonodi AC, Gross GW, Sun CC, Agthe AG, Xiao L, Waites KB, et
483 al. Necrotizing enterocolitis is associated with ureaplasma colonization in preterm infants.
484 Pediatric research. 2011;69(5 Pt 1):442-7.

485 29. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease.
486 Pediatric pulmonology. 2001;31(6):464-73.

30. Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for
prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis.
Neonatology. 2014;106(4):337-47.

490 31. Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia
491 in preterm infants: A systematic review and meta-analysis. Pediatric pulmonology.
492 2021;56(5):957-66.

493 32. Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of
494 Lactobacillus derivatives in maintaining vaginal health. Microbial cell factories.
495 2020;19(1):203.

33. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis
is improved by a standardized method of gram stain interpretation. Journal of clinical
microbiology. 1991;29(2):297-301.

499 34. Kiss H, Kögler B, Petricevic L, Sauerzapf I, Klayraung S, Domig K, et al.
500 Vaginal Lactobacillus microbiota of healthy women in the late first trimester of
501 pregnancy. BJOG : an international journal of obstetrics and gynaecology.
502 2007;114(11):1402-7.

503 35. Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I,
504 et al. Characterisation of the vaginal Lactobacillus microbiota associated with preterm
505 delivery. Scientific reports. 2014;4:5136.

36. Payne MS, Newnham JP, Doherty DA, Furfaro LL, Pendal NL, Loh DE, et al.
A specific bacterial DNA signature in the vagina of Australian women in midpregnancy
predicts high risk of spontaneous preterm birth (the Predict1000 study). American journal
of obstetrics and gynecology. 2021;224(2):206.e1-.e23.

510 37. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, et al.

511 Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners. Journal of 512 bacteriology. 2011;193(5):1034-41.





\*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

# Figure





\*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

# Figure

Figure 2 Change of microbial load of vaginal Ureaplasma DNA before and after antibiotic regimen



\*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

# Figure